Humoral Immunogenicity of 3 COVID-19 Messenger RNA Vaccine Doses in Patients With Inflammatory Bowel Disease
Trevor Schell, Keith L. Knutson, Sumona Saha, Arnold Wald, Hiep Phan, Mazen Almasry, Kelly Chun, Ian Grimes, Megan Lutz, Mary S. Hayney, Francis A. Farraye, Freddy Caldera
Abstract
Lay Summary Herein, we evaluated the humoral immunogenicity of a third coronavirus disease 2019 messenger RNA vaccine dose in patients with inflammatory bowel diseases. All patients displayed a humoral immune response, and median antibody concentrations were higher after the third dose than after completion of the 2-dose series.
Topics & Concepts
ImmunogenicityInflammatory bowel diseaseCoronavirus disease 2019 (COVID-19)MedicineImmunologyMessenger RNADiseaseSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Virology2019-20 coronavirus outbreakImmune systemInternal medicineBiologyOutbreakInfectious disease (medical specialty)GeneBiochemistrySARS-CoV-2 and COVID-19 ResearchImmune responses and vaccinationsVaccine Coverage and Hesitancy